Novartis Acquires Global Rights to Sironax Brain-Delivery Platform for $125 Million
The Swiss pharmaceutical group has exercised its option to acquire Sironax’s technology for transporting large therapeutic molecules across the blood-brain barrier. Novartis has exercised its exclusive option to acquire full global rights to Sironax’s…
ByteDance’s AI Drug Discovery Spinout Anew Labs Reportedly Raises $290 Million
Anew Labs, the AI drug discovery company spun out of TikTok owner ByteDance, has reportedly completed a $290 million first independent financing round. China’s PEdaily reported the raise citing sources; Reuters separately reported the same amount based…
Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…
Genocury’s In Vivo CAR-T JY231 Shows Early Promise in Refractory Neurologic Autoimmune Diseases
A Chinese research team has reported encouraging early clinical results for JY231, an investigational lentiviral in vivo CD19 CAR-T therapy that generates therapeutic CAR-T cells directly inside the patient’s body, potentially eliminating two of…
Convergen Closes $15 Million Financing to Advance Novel Protein Degradation Therapies for Neurodegenerative Diseases
Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for…
TYK Medicines Wins China Approval for Asandeutertinib in EGFR-Mutant NSCLC With Brain Metastases
China’s NMPA has granted conditional approval to asandeutertinib (TY-9591), TYK Medicines’ brain-penetrant, deuterated EGFR inhibitor, for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer with central nervous…
DualityBio Partners with Genentech in $1B-Plus Next-Generation ADC Collaboration Built Around Novel Payload Platform
China’s Duality Biotherapeutics has signed a global research, development and licensing agreement with Roche’s Genentech to develop a new generation of antibody-drug conjugates designed to overcome resistance to payloads used in today’s…
Biokin’s Iza-Bren Hits Phase 3 PFS Endpoint in HR+/HER2− Breast Cancer, Marking 5th Phase 3 Success
Biokin Pharmaceutical’s first-in-class EGFR×HER3 bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren; BL-B01D1) has delivered another positive Phase 3 readout, meeting the progression-free survival endpoint in previously treated…
Leads Biolabs’ Opamtistomig NDA Accepted in China, Setting Up Potential World-First 4-1BB Therapy
Nanjing Leads Biolabs announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has formally accepted the New Drug Application (NDA) for Opamtistomig (LBL-024), the company’s internally developed…
BIC 2026 8th Asia Biologics Innovation Conference
BIC 2026 will showcase next-generation modalities—from ADCs and siRNA to iPSCs and peptides—to advance drug R&D and clinical progress in cardiorenal, metabolic, and liver diseases. A key focus will be placed on pioneering strategies that transition…